SCHEMBL4869119

SCHEMBL4869119

NC(=O)CN(c1ccc(Cl)cc1Cc1ccccc1Cl)S(=O)(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 5/20 0.38
NFE2L2 Q16236 5/20 0.38
PTGER1 P34995 4/20 0.37
THRB P10828 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
FDFT1 P37268 1/20 0.36
DAGLA Q9Y4D2 2/20 0.35
TBXA2R P21731 1/20 0.35
PTGFR P43088 1/20 0.35
PTGER3 P43115 1/20 0.35
PTGER2 P43116 1/20 0.35
PTGIR P43119 1/20 0.35
PTGDR Q13258 1/20 0.35
KCNJ5 P48544 1/20 0.34
KCNJ3 P48549 1/20 0.34
NR1H4 Q96RI1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3253245 0.89 KEAP1 (0.51) KEAP1NFE2L2PTGER1THRB
SCHEMBL3256139 0.89 PTGER1 (0.44) KEAP1NFE2L2PTGER1THRBMEN1
SCHEMBL3249159 0.89 KEAP1 (0.48) KEAP1NFE2L2PTGER1THRBMEN1
SCHEMBL4867374 0.86 KEAP1 (0.43) KEAP1NFE2L2PTGER1THRBMEN1
SCHEMBL3255469 0.86 KEAP1 (0.43) KEAP1NFE2L2PTGER1THRBMEN1
SCHEMBL3247110 0.86 THRB (0.45) KEAP1NFE2L2PTGER1THRBMEN1
SCHEMBL3251187 0.85 THRB (0.44) KEAP1NFE2L2PTGER1THRBMEN1
SCHEMBL3244429 0.85 PTGER1 (0.42) KEAP1NFE2L2PTGER1THRBMEN1
SCHEMBL3250637 0.84 FDFT1 (0.39) KEAP1NFE2L2PTGER1THRBMEN1
SCHEMBL4860804 0.83 KEAP1 (0.43) KEAP1NFE2L2PTGER1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 KEAP1 3317/4885NFE2L2 2700/4885PTGER1 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.